If you find any of the dividend record is wrong or duplicated, please contact me.
| Year | Yield | Total | Amount | Ex Date | Pay Date | Particulars |
|---|---|---|---|---|---|---|
| 2024 | 7.60% | CHF 4 | CHF4 | 2024-05-13 | 2024-05-15 | Rate: CHF 4 Per Security |
| 2023 | 6.65% | CHF 3.5 | CHF3.5 | 2023-05-09 | 2023-05-11 | Rate: CHF 3.5 Per Security |
| 2021 | 5.70% | CHF 3 | CHF3 | 2021-05-10 | 2021-05-12 | Rate: CHF 3 Per Security |
| 2020 | 5.22% | CHF 2.75 | CHF2.75 | 2020-04-30 | 2020-05-05 | Rate: CHF 2.75 Per Security |
| 2018 | 5.22% | CHF 2.75 | CHF2.75 | 2018-05-07 | 2018-05-11 | CHF 2.75 |
| 2017 | 5.22% | CHF 2.75 | CHF2.75 | 2017-04-26 | 2017-05-03 | CHF 2.75 |
| 2016 | 4.75% | CHF 2.5 | CHF2.5 | 2016-04-25 | 2016-04-28 | CHF 2.5 |
| 2015 | 4.75% | CHF 2.5 | CHF2.5 | 2015-04-09 | 2015-04-14 | CHF 2.5 |
| 2014 | 4.08% | CHF 2.15 | CHF2.15 | 2014-04-22 | 2014-04-25 | CHF 2.15 NET OF TAX |
| 2013 | 4.08% | CHF 2.15 | CHF2.15 | 2013-04-11 | 2013-04-16 | CHF 2.15 |
| 2012 | 4.08% | CHF 2.15 | CHF2.15 | 2012-04-09 | 2012-04-12 | CHF 2.15 |
ListedDate: 21 October 2011 on SGX Mainboard
The share price is in SGD. The dividends are paid in CHF
Address: Muenchensteinerstrasse 38 , CH-4002 Basel, Switzerland
Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999. Lonza is a supplier to the pharmaceutical, healthcare and life sciences industries with products and services spanning from research to final product manufacture to meet customers’ needs. The products Lonza manufacture for the life sciences industry can be characterised as very complex molecules which are manufactured in a highly regulated environment and will end up in the body of human beings or animals. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. The Group has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. The Group provides cell-based research, endotoxin detection and cell therapy manufacturing. The Group is also a provider of high value chemicals and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. To provide optimal support to its customers, the Group is organized into three business divisions, namely, Custom Manufacturing, Life Science Ingredients and Bioscience, which focus on specific sets of customers and their needs.
© 2024 Dividends.sg / More Countries